Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"
NCT ID: NCT03492528
Last Updated: 2022-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
530 participants
INTERVENTIONAL
2019-07-05
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined.
Primary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology.
Secondary objectives
* To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data.
* To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies
NCT06664528
Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study
NCT06268535
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
NCT06692894
Breast Cancer Long-term Outcome of Cardiac Dysfunction
NCT01904331
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors
NCT03498040
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiovascular patients treated for a cancer
blood samples
blood samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood samples
blood samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Minor or major patient under guardianship
* Pregnant or breastfeeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique Hopitaux De Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
jean-olivier ARNAUD
Role: STUDY_DIRECTOR
Assistance Publique-Hôpitaux de Marseille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiatnce Publique Hopitaux de Marseille
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020 Jan;8(1):e000261. doi: 10.1136/jitc-2019-000261.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A03362-51
Identifier Type: OTHER
Identifier Source: secondary_id
2017-50
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.